Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Sonia Maldonado-Schmidt"'
Autor:
Guru Subramanian Guru Murthy, Antoine N. Saliba, Aniko Szabo, Alexandra Harrington, Sameem Abedin, Karen Carlson, Laura Michaelis, Lyndsey Runaas, Arielle Baim, Alex Hinman, Sonia Maldonado-Schmidt, Annapoorna Venkatachalam, Karen S. Flatten, Kevin L. Peterson, Paula A. Schneider, Mark Litzow, Scott H. Kaufmann, Ehab Atallah
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Azacitidine/venetoclax is an active regimen in patients with newly diagnosed AML. However, primary or secondary resistance to azacitidine/venetoclax is an area of unmet need and overexpression of MCL-1 is suggested to be a potential resistance mechan
Externí odkaz:
https://doaj.org/article/950acd891d7543f3b377e2a769eccff7
Autor:
Ehab L. Atallah, Alexis Visotcky, Kathryn E Flynn, Mei-Jie Zhang, Jerald P. Radich, Jay Yang, Vivian G. Oehler, Srinivas K. Tantravahi, B. Douglas Douglas Smith, Javier Pinilla Ibarz, Kendra Sweet, Michael Mauro, Brian J. Druker, James E. Thompson, Sonia Maldonado-Schmidt, Arielle Baim, Charles A. Schiffer, Vamsi K. Kota, Jorge E. Cortes
Publikováno v:
Blood. 140:3885-3886
Autor:
Karen Carlson, Mark R. Litzow, Arielle Baim, Althea Thomas, Aniko Szabo, Laura C. Michaelis, Alexandra M. Harrington, Sameem Abedin, Sonia Maldonado-Schmidt, Walter L. Longo, Lyndsey Runaas, Alexander Hinman, Ehab Atallah, Scott H. Kaufmann, Guru Subramanian Guru Murthy
Publikováno v:
Blood. 138:2347-2347
Background: Outcomes of patients with relapsed/refractory AML (RR-AML) have remained poor. Therapy with venetoclax based combinations in this setting leads to CR/CRi rates of 21-49% (DiNardo CD et al. Am J Hematol 2018, Aldoss I et al. Haematologica
Publikováno v:
Hematology Week; 7/2/2024, p1832-1832, 1p